Veradermics, Incorporated filed a Current Report on Form 8-K with the SEC on August 11, 2026, announcing the issuance of a press release covering its financial results for the quarter ended June 30, 2026.

Key Highlights

  • Filing date: August 11, 2026, with the earliest event date also reported as August 11, 2026.
  • Quarter covered: Financial results for the quarter ended June 30, 2026.
  • Exchange and ticker: Common Stock (par value $0.00001 per share) trades on NYSE:MANE.
  • Emerging growth company: Veradermics, Incorporated is designated as an emerging growth company under applicable SEC rules.
  • Signed by: Reid Waldman, M.D., Chief Executive Officer, on August 11, 2026.
  • Exhibit furnished: Press release (Exhibit 99.1) is furnished, not filed, under Item 2.02.

Veradermics Reports Q2 2026 Results via Press Release

On August 11, 2026, Veradermics, Incorporated, a Delaware-incorporated company headquartered at 470 James Street, New Haven, CT 06513, filed a Current Report under Item 2.02 (Results of Operations and Financial Condition) of Form 8-K. According to the filing, the company issued a press release on the same date announcing its financial results for the quarter ended June 30, 2026. The full text of that press release is attached as Exhibit 99.1 to the report.

The filing notes that the information contained in Item 2.02, including Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ... or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing." The company also included a Cover Page Interactive Data File (Exhibit 104) embedded within the Inline XBRL document.

The registrant's Commission File Number is 001-43097 and its IRS Employer Identification Number is 84-3304423. Veradermics indicated it has not elected to use the extended transition period for complying with new or revised financial accounting standards available to emerging growth companies under Section 13(a) of the Exchange Act.

What Was Disclosed

Veradermics, Incorporated disclosed, via an 8-K filed August 11, 2026, that it issued a press release reporting financial results for the quarter ended June 30, 2026. The press release (Exhibit 99.1) is furnished, not filed, under Item 2.02.